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 Lactic acid bacteria (LAB) improved motor behavior in a Parkinsonism mouse 
model. 
 LAB administration increased tyrosine hydrolase positive cells in the brain. 
 LAB administration decreased the levels of pro-inflammatory cytokines in 
serum. 
 LAB administration increased IL-10 in serum and brain.  
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Objectives: Parkinson’s Disease (PD) is a neurodegenerative process affecting motor 
function that involves an inflammatory response and B vitamins deficiencies. The aim 
of this study was to evaluate the effect of B-group vitamin producing and 
immunomodulatory lactic acid bacteria (LAB) in a murine model of PD.  
Methods: The effect of Lactobacillus plantarum CRL 2130 (a riboflavin producer), 
Streptococcus thermophilus CRL 807 (an immunomodulatory strain) and Streptococcus 
thermophilus CRL 808 (a folate producer) were evaluated individually and as a mixture 
in mice injected with 1-methyl-4-fenil-1,2,3,6-tetrahidropiridina (MPTP). Motor 
capacity, tyrosine hydrolase (TH) in brain and cytokine concentrations in serum and in 
brain tissues were evaluated in MPTP treated mice after bacterial supplementation. 
Results: Mice receiving the selected LAB showed significantly improved motor skills 
compared to those that did not receive bacterial supplementation. When given the 
mixture of all 3 strains together, animals had higher brain TH+ cell counts, decreased 
the inflammatory cytokines IL-6 and TNF-α in serum and increased the anti-
inflammatory cytokine IL-10 in serum and brain tissues compared to animals that did 
not receive LAB supplementation.  
Conclusions: The results showed the potential of a selected LAB mixture to improve 
motor behavior and neuroinflammation in PD. This probiotic mixture could be used as 
an adjunct treatment in the control of PD.  
 
Keywords: Lactic acid bacteria; Parkinson’s disease; probiotic; inflammation; motor 
behavior; animal model.  




Parkinson’s disease (PD) as well as other neurological disorders has historically 
been studied within the central nervous system (CNS); however, peripheral influences 
have also been implicated in their onset and/or progression. In fact, emerging data 
propose bidirectional communication between the intestine and the brain; recent studies 
suggest that intestinal toxins can induce the formation of alpha synuclein (α-syn) 
aggregates in the enteric nervous system, which then can reach the CNS through the 
vagus nerve [1]. The intestinal microbiota has also been shown to control the 
differentiation and function of immune cells in the intestine, periphery and brain [2]. It 
has been reported that the total counts of intestinal bacteria decrease during PD 
progression [3]; however, it is unsure if modifications of the intestinal microbiota are 
the cause or consequence of this disease.  
The CNS has traditionally been considered immunologically privileged due to 
the protection conferred by the blood-brain barrier. Neurons of the CNS are actively 
involved in control of the immune response by modulating the function of glial cells 
and T lymphocytes [4]. Pro-inflammatory cytokines produced in peripheral tissues are 
able to modulate neuronal circuits in the CNS through specific receptors expressed by 
neurons, and this response can prevent and/or induce eventual immune-mediated brain 
damage [4]. 
Researches about the modulation of the gut-brain axis via the gastrointestinal 
microbiota are still emerging. Probiotics, prebiotics and synbiotics can beneficially 
modify the gut microbiota composition and influence the gut-brain axis [5, 6]. Recently, 
the term “psychobiotic” has been associated to a group of probiotics that can affect the 
CNS [7]. Cerdó et al., (2017) showed that these supplements have been associated with 
benefits against different CNS disorders; however, the molecular mechanisms 
associated to the gut’s microbial modulation and its influences on the CNS are not fully 
understood [8]. The need to individualize specific prebiotic compounds and probiotic 
strains for nutrition and lifestyle medicine practitioners has been recently described [9]. 
Author highlighted that simple dietary interventions as well as moderate levels of 
physical activity and the use of stress management techniques, pose potential benefit to 
management the intestinal microbiota. In this sense, current treatments for PD not only 
include medical and surgical therapies, but also include the management of diet and 
nutritional supplements.   
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Regarding vitamins, increases in blood homocysteine (Hcy) concentrations has 
been reported in PD patients, and it is known that high intakes of B vitamins, decrease 
the level of Hcy; however; information regarding the direct association between PD and 
B vitamins is still very scarce [10]. Riboflavin (vitamin B2) can be neuroprotective by 
decreasing oxidative stress, mitochondrial dysfunction, neuroinflammation and 
glutamate excitotoxicity. Another B group vitamin involved in the metabolism of Hcy is 
folate (vitamin B9). Patients suffering PD presented deficiency of folates [11]; and the 
beneficial effect of folate intake in levodopa-treated PD patients has been reported [12].  
The capacity of lactic acid bacteria (LAB) to produce vitamins in novel 
functional foods or in situ once the microorganisms colonize the host intestine has been 
reported [13]. Previously, our group has demonstrated that selected LAB are able to 
produce B group vitamins (riboflavin and folates) and had beneficial effects against 
intestinal inflammatory diseases using animal models [14-16]. It has also been shown 
that certain immune-modulating strains of LAB also confer anti-inflammatory effects 
[17]. However, the potential benefits of these LAB on neurological diseases have not 
yet been evaluated.  
Based on this information, the aim of the present work was to evaluate the 
neuroprotective effect associated to the anti-inflammatory properties of a LAB mixture 
composed of two vitamins producing strains (Lactobacillus plantarum CRL 2130 and 
Streptococcus thermophilus CRL808, riboflavin and folate producers, respectively) and 
an immune-modulator strain (Streptococcus thermophilus CRL807) by using an in vivo 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonism model.  
 
Materials and Methods 
 
Bacterial mixture preparation 
  
The bacterial strains were obtained from CERELA Culture Collection (Tucumán, 
Argentina): Lactobacillus (L.) plantarum CRL 2130, a riboflavin-overproducing strain 
[18]; Streptococcus (S.) thermophilus CRL 808, a folate-producing strain [19]; and S. 
thermophilus CRL 807, a strain with immunomodulatory properties [20]. Each LAB 
was grown individually then mixed when required following previously described 
procedures [14]. Mice received 100 µl of the bacterial suspension that contain 8 ± 2 × 
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108 c.f.u./ml of each strain (L. plantarum CRL 2130, S. thermophilus CRL 808, and S. 




Eight-week-old male C57BL/6 mice (20–30 g) were obtained from the animal 
facility of CERELA and were tagged and distributed in metal housing cages at constant 
room temperature (20±2ºC) and relative humidity (60%), with a 12-h light-dark cycle. 
Food and water was provided ad libitum. Animals were treated according to a protocol 
approved by the Ethical Committee of CERELA (CRL-BIOT-LI-2008/1B). 
 
MPTP / probenecid Parkinsonism model 
 
Mice were divided into 8 groups (n = 7 for group). MPTP group was injected 
subcutaneously with 250 mg/kg of body weight of probenecid (Santa Cruz 
Biotechnology, Dallas, TX, USA), then intraperitoneally (i.p) with MPTP hydrochloride 
(Sigma, St. Luis, MO, USA) at 20 mg/kg of body weight in saline solution and received 
orally saline solution. MPTP/CRL 2130, MPTP/CRL 808, MPTP/CRL 807 and 
MPTP/MIX groups were injected with probenecid and MPTP, and orally administered 
L. plantarum CRL 2130, S. thermophilus CRL 808, S. thermophilus CRL 807 or the 
bacterial mixture, respectively. Control and MIX groups were injected (subcutaneously 
and itraperitonally) saline solution and oral administered saline solution or bacterial 
mixture, respectively. Probenecid was injected 30 minutes before the MPTP, in order to 
reduce its elimination and increase the rate of passage to the blood brain barrier [21]. 
Mice received a total of 5 injections of 100 µl of MPTP and 100 µl of probenecid or 
saline solution at the middle of the morning at an interval of 4 days. LAB (or saline 
solution) were administered orally by using a gavage syringe daily during the afternoon 




Motor behavior tests were performed during the afternoon. For each test, mice were 
trained for 3 consecutive days (3 tests each day) before starting the MPTP treatment. 
The first test recorded was the day before the first MPTP treatment (day 0) and the last 
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one 3 days after the last MPTP treatment (day 20). In order to avoid detect acute 
pharmacological effects MPTP; all behavioral tests were performed on the third day 
after each MPTP injection. Animals were monitored using the different tests during the 
experimental protocol by the same observer. 
 
Pole test 
The pole test is useful for predicting the degree of bradykinesia and the ability to 
balance the movement of mice [22]. Mice were placed face up on the top of a vertical 
wooden pole (1.3 cm of diameter and 90 cm of height) and they had to orient 
downwards to descent. The operator took the time (in seconds) that they reached the 
base. The base of the pole was placed in the home cage. 
 
Transversal beam test 
This test is used to measure motor performance [23]. It consisted of a wooden 
bar (1.3 cm of diameter and 90 cm of length) deposited at a height of 35 cm from the 
base with an angle of 15º. The animals were trained to cross the length of the bar 
starting at the higher section and ending in the lower section that led directly to the 
animal's cage. Each mouse crossed the bar in 3 attempts while the operator recording 
the time in seconds. 
 
Nasal bridge adhesive removal test 
This trial is a stimulation test used to motor response to sensory sensitivity [24]. 
Small adhesive tape (3 mm of diameter) was placed on the nasal bridge of each mouse, 
and the time to remove it was recorded in order to average the time in 3 consecutive 
attempts. All testing was performed in the animal’s home cage, and cage mates were 
temporarily removed during testing because they can interfere with stimulus removal. If 




Three days after the last MPTP injection animals were euthanized by cervical 
dislocation after being anesthetized with a mix of ketamine hydrocholoride (König 
Laboratory, Buenos Aires, Argentina) and xylazine (Bayer: División Sanidad Animal, 
Buenos Aires, Argentina). Half of the brain was removed, immediately place on an ice-
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cold surface and snap-frozen in liquid nitrogen for future determination of cytokines. 
The other half of the brain was stored for 24 h in 10% paraformaldehyde / PBS (pH 7.4) 
to be then embedded in paraffin. Blood samples were centrifuged at 1,000 x g 10 min 
and the serums were stored at -80 °C. 
 
Tyrosine hydroxylase (TH) immunohistochemistry 
 
The sections of brain tissue samples were cut at 5 µm with a microtome using 
positively treated slides in order to find the SNpc. After paraffin removing and 
rehydration, the antigenic recovery was carried out with washes in 0.1 M citrate buffer 
(pH 6.8 tris-HCl) at 37 °C and at room temperature. Endogenous peroxidase activity 
was blocked with hydrogen peroxide. The tissues were incubated with the primary 
antibody for TH (F-11, human, mouse monoclonal IG2a, Santa Cruz Biotechnology, 
CA, USA) at 4 °C overnight. Then, sections were incubated with the biotinylated 
antibody (Santa Cruz Biotechnology, CA, USA) at 37 °C for 1h 30 min. Samples were 
incubated with avidin-biotin peroxidase reactive complex (Thermo Scientific, Rockford, 
USA)  and  colored with DAB (3,3-diaminobenzidine, Thermo Scientific, Rockford, 
USA ) in the presence of hydrogen peroxide. Subsequently, they were stained with 
hematoxylin and mounted with Canada balsam.  
 All tissue cuts were viewed using a microscope, and the images were captured 
by digital camera. The quantitative analysis of TH+ neurons in the SNpc was carefully 
delimited according to the brain atlas of Paximos et al. [25] and the cells were counted 
in 12 fields at 1000X of magnification. 
 
Measurement of cytokines in mice brain and serum 
 
Brains stored in liquid nitrogen were thawed and homogenized following a 
previously described protocol [26]. Cytokines were analyzed for both serum and brain 
samples. The concentrations of cytokines, interleukin-10 (IL-10), tumor necrosis factor-
α (TNF-α), IL-6, and monocyte chemoattractant protein-1 (MCP-1) were determined by 
using Mouse Flex Sets (BD Bioscience, San Diego, CA, USA) following the protocols 
described for cytometric bead array (CBA). For the brain samples, the results were 
expressed in relation to the total protein concentration measured in the sample. 
 





All data were analyzed with GraphPad Prism 6 software and ANOVA general 
linear model followed by Tukey's post hoc test to determine the differences between 
groups. The values for all measurements were expressed as the mean ± standard 
deviation (SD). The experiment was repeated twice; the results from both trials were 




LAB alleviated motor impairments induced by MPTP 
 
The injections of MPTP gradually induced motor impairment starting at the third 
injection compared to the basal data. Mice from MPTP group delayed completing all 
the tests compared to the Control group. These differences were significant (p < 0.05) in 
all time points for the pole and nasal bridge adhesive removal tests, and since the 8th 
day for the transversal beam test (Fig. 2). The administration of LAB mixture to mice 
injected with MPTP significantly alleviated the motor deficiencies induced by MPTP 
and maintained a performance similar to the Control group and also to mice who 
received LAB mixture, both without neurotoxin (Fig. 2A, 2C and 2E). No significant 
differences were observed between MIX and Control group. For this experiment, the 
individual LAB were administered to mice injected with MPTP to investigate if the 
benefits observed with the LAB mixture could be associated to one specific strain. The 
results obtained did not show significant differences between the strains in most of the 
time points evaluated. All MPTP/LAB groups completed the three tests at the end of the 
experiment in a time significantly (p < 0.05) lower than the mice from MPTP group. 
The comparisons with the healthy animals (Control group) showed that for the pole and 
transversal beam tests, the performance was similar to those observed in mice from 
MPTP/MIX group, with times similar or even lower than the Control group (Fig. 2B 
and 2D). However, for the nasal bridge adhesive removal test, mice that received the 
individual LAB did not reach the average time recorded in the Control group (Fig 2F). 
The results showed that each individual strain exerted benefits against the motor 
impairment induced by MPTP, thus each one can contribute to the effect observed with 
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the mixture; moreover, the LAB mixture was more effective in order to improve all the 
tests evaluated.   
 
Effect of LAB MIX administration on dopaminergic neuronal loss induced by MPTP 
 
To relate the motor behavior with the loss of dopaminergic cells, TH-
immunoreactivity was evaluated in the SNpc of control mice and mice injected MPTP 
and that received or not the LAB mixture. The number of TH+ cells in the SNpc of mice 
decreased significantly (p ˂ 0.05) in MPTP group compared to the Control. The 
administration of LAB MIX in mice injected with MPTP (MPTP/MIX group) 
maintained the number of TH+ cells without significant differences (p > 0.05) compared 
with the Control group; similar to the results obtained in mice fromMIX group, without 
the neurotoxin (Fig. 3). 
 
Effect of the LAB mixture administration and MPTP injections on serum cytokine levels 
 
Systemically, in serum, the MPTP group showed significant increases (p ˂ 0.05) 
of IL-6 and TNF-α compared to Control group. Instead, these pro-inflammatory 
cytokines decreased significantly (p ˂ 0.05) in MPTP/MIX group, and maintained 
values similar to the Control. The administration of LAB MIX to healthy mice did not 
modify these cytokines in serum (Fig. 4A and 4B).  On the other hand, the 
administration of LAB mixture to mice injected MPTP (MPTP/MIX group) or not 
(MIX group) showed significant increases (p ˂ 0.05) for the anti-inflammatory cytokine 
IL-10 compared to both MPTP and Control groups (Figure 4C). 
MCP-1 did not show significant differences (p ˂ 0.05) between the experimental 
groups (Fig. 4D). 
 
Effect of the LAB mixture administration and MPTP injections on brain cytokine levels 
 
The analysis of cytokines in the brains showed significant increases (p ˂ 0.05) 
for MCP-1 and IL-6 in mice from MPTP group compared to the Control group. LAB 
mixture administration did not modify significantly these cytokines compared to MPTP 
group; however, no significant differences were also observed compared to the groups 
without MPTP due to the variation of the values obtained between the mice from 
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MPTP/MIX group (Fig. 5A and 5D). TNFα increased significantly in MPTP/MIX 
group compared to MPTP group; moreover no significant differences were obtained 
compared to Control group (Fig. 5B). The highest concentrations for IL-10 were 
obtained in MPTP/MIX group but without significant differences (p > 0.05) with the 




The possibility that selected microorganisms administered orally, can beneficially 
affect neurological, neurophysiological and neuroimmunological aspects of the host, has 
aroused the interest of new studies. Although there are recent works that show the 
potential of certain probiotics to improve the quality of life and some physiological 
effects associated with PD, little is known about the possible mechanisms involved in 
these benefits [5, 6, 27, 28]. In addition, many studies show that dietary factors such as 
B vitamin deficiency are involved in the etiology of PD and that the administration of 
these vitamins could reverse some symptoms of this pathology [10-12]. In the present 
work a mixture of selected LAB (a ribloflavin producer, a folate producer and a strain 
with anti-inflammatory properties associated to the modulation of the host’s immune 
response) was evaluated by using a MPTP induced parkinsonism model.  
Results obtained showed that the administration of the LAB mixture improved the 
motor behavior altered by MPTP, and each selected strain can contribute to the benefits 
observed with the mixture. Behavioral tests do not detect acute pharmacological actions 
of MPTP/MPP+, they demonstrate neurodegenerative damage [23]. In this sense, it was 
reported that a probiotic mix diminished behavior disorders in MPTP- and rotenone- 
induced models by increasing butyrate level [29]. Likewise, SLAB51 probiotic 
formulation was able to counteract behavioral impairment induced by 6-
hydroxydopamine (6-OHDA) inoculation in a PD mouse model, restoring the healthy 
control conditions. This effect was associated to the activation of peroxisome 
proliferator activated receptor γ (PPARγ) that may generate anti-inflammatory and 
antioxidant activities as well as the increase in Brain Derived Neurotrophic Factor 
(BDNF), involved in neuroprotection and neuronal survival [30]. Similarly to the results 
in animals’ models, a clinical trial with PD patients demonstrated that compared to 
placebo group, patients who consumed a probiotic mixture showed favorable impacts 
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on movement parameters altered in PD [27]. Authors related these benefits with the 
improvement of some metabolic parameters.  
Tyrosine hydroxylase is a key enzyme in the production of dopamine by 
dopaminergic neurons and is affected in PD as well as in MPTP induced and other 
animal models. Recently, it was demonstrated that long term administration of a 
mixture containing six probiotic strains to transgenic MitoPark PD mice significantly 
reduced the motor impairments and preserved TH+ cells in the SNpc [31]. Likewise, the 
evaluation of these cells in our model showed that motor behavior improvements 
observed with the LAB mixture administration to mice injected MPTP were associated 
to maintenance of TH+ cells’ number in the SNpc. The results also showed that LAB 
administration by itself did not induce any effects on the number of dopaminergic 
neurons compared to the Control group. Similarly, other probiotic mixture showed the 
same protective effect against TH+ cells in a MPTP induced model; however, at 
difference of our model, the probiotics were administered preventively (one month 
before MPTP) and the neurotoxin was injected four times in one single day [29]. Our 
model can represent better the chronic state of PD that could be also associated with 
intestinal microbial dysbiosis. However, the study of the intestinal microbiota is a 
limitation of our work and will be analyzed in the future. In this sense, it was reported 
that similar to intestinal microbial dysbiosis observed in PD patients, MPTP-induced 
model in mice with five neurotoxin injections induced modifications of intestinal 
bacteria [32]. 
The immune response was evaluated systemically and locally in the brain of mice 
injected MPTP considering the anti-oxidant/anti-inflammatory effect associated to our 
LAB blend against other pathologies [14].  Peripheral inflammation is implicated in 
many neurodegenerative diseases such as in PD [33]. However, there is no general 
consensus whether the reactive microglia are a cause or effect of neuron loss during 
disease progression. In the present work, the serum concentration of IL-6 and TNF-α 
increased in mice from MPTP group; and LAB blend administration maintained the 
levels of both cytokines similar to the Control group. Elevated serum concentrations of 
TNF-α and IL-6 have been associated with increased risk of PD [34].Our results were 
similar to other described for MPTP-induced models in which the beneficial effects 
were related to decrease of systemic inflammation [35]. 
Brains from PD patients and animal models showed evidence for 
neuroinflammation with increased pro-inflammatory cytokines from a classical M1 
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activation of the microglia [36].  Similarly, our results showed that IL-6 and MCP-1 
increased significantly in the brains form MPTP group, and LAB mixture 
administration decreased these cytokines in some animals. However, the variations for 
these cytokines between the mice from MPTP/MIX group, maintained the group values 
without significant differences with the healthy control. IL-6 is an important cytokine in 
the CNS, and several neurological pathologies are associated with increased expression 
of this cytokine in brain [37]. MCP-1 has been described as a biomarker positively 
correlated with PD progression [38]. In addition, LAB mixture administration to MPTP 
injected mice increased significantly the IL-10 concentration in brains compared to 
Control animals. In this sense, the neuroprotective effect in PD has been associated to 
an activated M2 phenotype of microglia with release of anti-inflammatory cytokines 
such as IL-10 and TGF-β [36]. Thus, LAB administration can balance different 




The results obtained showed the potential of a selected LAB mixture to improve 
motor behavior impaired in PD. Different mechanism of action can be involved in this 
effect, some of them associated to the production of B vitamins and the anti-oxidant 
effect of them, and others are related to the modulation of the host’s immune response 
in order to avoid an exacerbated inflammation systemically and locally in the brain. 
Other mechanisms such as the modulation of the intestinal microbiota could also be 
involved and will be evaluated in future studies. 
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Fig. 1. Experimental model of Parkinson Disease used in this study. Day 0 signifies 
when experimental procedure starts with bacterial supplementation. Numbers in arrows 
show days from experimental start. Grey arrows show when motor function behavior 
were evaluated (days 0, 4, 8, 12, 16, 20), the needles show the days when 
MPTP/probenecid were injected and black arrow shows the day when mice were 
sacrificed and the experiment finished (day 22). 
  
Fig. 2. Motor behavior of animals. Mice were testing for pole test (A, B), transversal 
beam test (C, D), and nasal bridge adhesive removal test (E, F). In all figures Control 
group are healthy animals and MIX group are healthy animals that received the 
probiotic blend; MPTP groups are animals that received the neuropathological drug 
MPTP: MPTP/MIX, MPTP/CRL2130, MPTP/CRL807 MPTP/CRL808 groups are 
MPTP treated animals that received the probiotic blend (MIX) or the individual strains. 
Results are the average (n=14) with the standard deviation for each group and time 
point. Statistical analysis is shown for the three last time points, * and # mean that the 
data are significantly (p < 0.05) different compared to Control and MPTP groups, 
respectively.  
 





Fig. 3. Tyrosine hydroxylase (TH) positive cells in the mice brain. TH positive cells 
were analyzed by immunohistochemistry in the brain tissues’ sections from mice. 
Results are the average (n=14) with the standard deviation of the number of positive 
cells counted in 12 fields at 1000X of magnification. * and # mean that the data are 
significantly (p < 0.05) different compared to Control and MPTP groups, respectively. 








Fig. 4. Effect of LAB blend and MPTP on serum cytokines. The concentration of 
cytokines: Interleukin-6 (IL-6), Tumor Necrosis Factor (TNF-α), IL-10 and monocyte 
chemoattractant protein-1 (MCP-1) were determined in blood serum samples obtained 
at the end of the experiment. Data are shown as mean ± SD (14 mice per group). * and # 
mean that the data are significantly (p <0.05) different compared to Control and MPTP 
groups, respectively. 




Fig. 5: Effect of LAB blend and MPTP on brain cytokines levels. The concentration of 
cytokines: Interleukin-6 (IL-6), Tumor Necrosis Factor (TNF-α), IL-10 and monocyte 
chemoattractant protein-1 (MCP-1) were determined in brain homogenates obtained at 
the end of the experiment. Data are shown as mean ± SD (14 mice per group) and 
expressed in relation to the total protein concentration measured in the sample. * and # 
mean that the data are significantly (p <0.05) different compared to Control and MPTP 
groups, respectively. 
         
